Medicare Enrolled

Dr. Tommasina Papa-Rugino, M.D.

Optician · Manahawkin, NJ
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
1140 ROUTE 72 W, Manahawkin, NJ 08050
6099788900
In practice since 2005 (20 years)
NPI: 1629050554 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Papa-Rugino from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Papa-Rugino? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Papa-Rugino

Dr. Tommasina Papa-Rugino is an optician specialist in Manahawkin, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Papa-Rugino performed 511 Medicare services across 433 unique beneficiaries.

Between the years covered by Open Payments, Dr. Papa-Rugino received a total of $51,081 from 66 pharmaceutical and/or device companies across 1605 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Papa-Rugino is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ 511 Medicare services $51,081 industry payments

Medicare Practice Summary

Medicare Utilization ↗
511
Medicare services
Bottom 33% in NJ for optician
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
433
Unique beneficiaries
$68
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~26 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
257 $56 $180
New patient office visit (30-44 min)
An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range.
118 $67 $242
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
101 $83 $250
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
35 $115 $360
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$51,081
Total received (2018-2024)
Avg $7,297/year across 7 years
Top 4% in NJ for optician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
66
Companies
1,605
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$29,501 (57.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$21,581 (42.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,644
2023
$4,053
2022
$4,151
2021
$3,625
2020
$2,879
2019
$7,985
2018
$25,745

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Biogen, Inc.
$398
ABBVIE INC.
$354
Eisai Inc.
$263
GENZYME CORPORATION
$257
JAZZ PHARMACEUTICALS INC.
$229
Amneal Pharmaceuticals LLC
$189
Neurocrine Biosciences, Inc.
$154
Otsuka America Pharmaceutical, Inc.
$136
ARGENX US, INC.
$85
BANNER LIFE SCIENCES, LLC
$81
Genentech USA, Inc.
$67
Lilly USA, LLC
$53
Lundbeck LLC
$49
EMD Serono, Inc.
$48
PFIZER INC.
$39
Alexion Pharmaceuticals, Inc.
$37
E.R. Squibb & Sons, L.L.C.
$36
Celgene Corporation
$28
Aucta Pharmaceuticals, Inc.
$23
SK Life Science, Inc.
$23
Abbott Laboratories
$23
NEUROPACE, INC.
$19
LivaNova USA, Inc.
$19
TG Therapeutics, Inc.
$18
ACADIA Pharmaceuticals Inc
$15
Top 3 companies account for 38.4% of 2024 payments
All-time payments by company (2018-2024) ›
GENZYME CORPORATION
$21,160
Supernus Pharmaceuticals, Inc.
$9,487
Biogen, Inc.
$3,174
EMD Serono, Inc.
$1,835
ABBVIE INC.
$1,522
UCB, Inc.
$1,209
Genentech USA, Inc.
$961
Teva Pharmaceuticals USA, Inc.
$952
Lilly USA, LLC
$722
LivaNova USA, Inc.
$612
Janssen Pharmaceuticals, Inc
$550
Alexion Pharmaceuticals, Inc.
$509
Eisai Inc.
$496
Avanir Pharmaceuticals, Inc.
$467
Novartis Pharmaceuticals Corporation
$448
Lundbeck LLC
$409
Amgen Inc.
$404
NOVARTIS PHARMACEUTICALS CORPORATION
$378
Amneal Pharmaceuticals LLC
$365
Neurelis, Inc.
$329
EISAI INC.
$301
E.R. Squibb & Sons, L.L.C.
$253
SK Life Science, Inc.
$251
Allergan, Inc.
$250
PFIZER INC.
$243
Abbott Laboratories
$231
JAZZ PHARMACEUTICALS INC.
$229
Neurocrine Biosciences, Inc.
$216
ACADIA Pharmaceuticals Inc
$210
ARGENX US, INC.
$205
ARBOR PHARMACEUTICALS, INC.
$202
BANNER LIFE SCIENCES, LLC
$194
Biohaven Pharmaceutical Holding Company Ltd.
$187
Otsuka America Pharmaceutical, Inc.
$176
Biohaven Pharmaceuticals, Inc.
$164
Celgene Corporation
$149
AbbVie Inc.
$149
Acorda Therapeutics, Inc
$139
Corium, LLC
$133
AbbVie, Inc.
$118
UPSHER-SMITH LABORATORIES LLC
$112
Alnylam Pharmaceuticals Inc.
$105
IMPEL PHARMACEUTICALS INC.
$85
Grifols USA, LLC
$83
AstraZeneca Pharmaceuticals LP
$75
Adamas Pharmaceuticals, Inc.
$53
Kyowa Kirin, Inc.
$52
Akcea Therapeutics, Inc.
$50
Mallinckrodt Hospital Products Inc.
$49
Upsher-Smith Laboratories LLC
$44
Mallinckrodt Enterprises LLC
$42
TG THERAPEUTICS, INC.
$41
Medtronic USA, Inc.
$39
Mallinckrodt LLC
$32
Endo Pharmaceuticals Inc.
$29
Impax Laboratories, Inc.
$29
Bayer HealthCare Pharmaceuticals Inc.
$28
Aucta Pharmaceuticals, Inc.
$23
NEUROPACE, INC.
$19
TG Therapeutics, Inc.
$18
CATALYST PHARMACEUTICALS, INC.
$18
Allergan Inc.
$15
Avion Pharmaceuticals
$14
MITSUBISHI TANABE PHARMA AMERICA, INC.
$14
US WorldMeds, LLC
$13
Currax Pharmaceuticals LLC
$13
Top 3 companies account for 66.2% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ADLARITY · AIMOVIG · AJOVY · AMPYRA · AMYVID · APOKYN · AUBAGIO · AUSTEDO · AVONEX · Adlarity · Aimovig · Austedo XR · BAFIERTAM · BOTOX · BRILINTA · BRIUMVI · Betaseron · Briviact · COMIRNATY · CONTRAVE · COPAXONE · CREXONT · Dhivy · Duopa · EMGALITY · EPIDIOLEX · EVUSHELD · Edarbyclor · Enspryng · FIRDAPSE · Fycompa · GILENYA · GOCOVRI · Gamunex-C · Horizant · INBRIJA · INFINITY · INGREZZA · Infinity DBS Pulse Generators · KESIMPTA · LEMTRADA · LYRICA · LYVISPAH · Leqembi · MAVENCLAD · MAYZENT · Mavenclad · Motpoly XR · NAMZARIC · NASCOBAL · NOURIANZ · NUEDEXTA · NUPLAZID · NURTEC ODT · Neupro · Neuromodulation Dspsbls and Accs · OCREVUS · ONPATTRO · ONZETRA Xsail · OXTELLAR XR · Ocrevus · Ocrevus Zunovo · PLEGRIDY · Ponvory · QUDEXY XR TOPIRAMATE EXTENDED RELEASE CAPSULES · QULIPTA · RADICAVA · RECLAIM · REXULTI · RNS Neurostimulator Kit · RYTARY · Rebif · SOLIRIS · SPINRAZA · STRENSIQ · Soliris · TECFIDERA · TEGSEDI · TOSYMRA · TOSYMRA SUMATRIPTAN NASAL SPRAY · TROKENDI XR · TYSABRI · Trudhesa · UBRELVY · ULTOMIRIS · VALTOCO · VNS - Sentiva · VNS THERAPY SENTIVA MODEL 1000 GENERATOR · VNS Therapy SenTiva Model 1000 Generator · VRAYLAR · VUMERITY · VYEPTI · VYVGART · VYVGART HYTRULO · Vimpat · XCOPRI · ZEMBRACE SYMTOUCH · ZEPOSIA · Zinbryta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (58%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in optician and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 4% for optician in NJ.

Looking for an optician specialist in Manahawkin?
Compare opticians in the Manahawkin area by procedure volume, costs, and industry payment transparency.
Browse opticians nearby

Geographic Context

Opticians within 10 mi
70
Per 100K population
10.8
County median income
$86,411
Nearest hospital
SOUTHERN OCEAN MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Papa-Rugino is a clinical cardiology specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 4% of NJ peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Papa-Rugino experienced with office visit, established patient (20-29 min)?
Based on Medicare claims data, Dr. Papa-Rugino performed 257 office visit, established patient (20-29 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Papa-Rugino receive payments from pharmaceutical companies?
Yes. Dr. Papa-Rugino received a total of $51,081 from 66 companies across 1,605 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Papa-Rugino's costs compare to other opticians in Manahawkin?
Dr. Papa-Rugino's average Medicare payment per service is $68. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Papa-Rugino) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →